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Purpose: We evaluated the delivery efficiency of intravenously injected large molecular agents, 
before and after disruption of the blood–brain barrier (BBB-D), induced by focused ultrasound 
(FUS) using various acoustic parameters.
Materials and methods: Male Sprague-Dawley rats were injected intravenously with Evans 
blue (EB) before or after BBB-D induction by pulsed FUS. We used a 1.0 MHz pulsed FUS 
with four acoustic power settings and an ultrasound contrast agent (UCA) at four different 
doses to induce BBB-D resulting from cavitation. The permeability of the BBB was assessed 
quantitatively based on the extravasation of EB. Contrast enhanced magnetic resonance imaging 
(MRI) was used to monitor the gadolinium deposition associated with FUS. Histological analysis 
was performed to examine tissue damage.
Results: The accumulation of EB in rat brain was found to be dependent on acoustic power and 
UCA dosage, regardless of whether EB administration occurred before or after FUS-induced 
BBB-D. Administration of EB followed by sonication resulted in greater EB extravasation 
than that for rats subjected to sonication prior to EB injection. To reduce tissue damage, EB 
extravasation was enhanced by first administering EB by intravenous injection, followed by 
sonication at reduced acoustic power or UCA dosage. The normalized signal intensity change 
in rat brains that received the same dose of UCA and sonicated after gadolinium injection was 
significantly greater than in rats undergoing sonication followed by gadolinium administration. 
Moreover, contrast enhanced MRI showed a more precise distribution of gadolinium in the brain 
when gadolinium was administered before sonication.
Conclusion: We demonstrated that a compound administered prior to sonication treatment 
promotes extravasation of the sonicated region. Thus, it is possible to optimize ultrasound 
parameters for lower sonication and reduced UCA doses, to induce BBB-D while minimizing 
damage to normal brain tissue.
Keywords: drug administration, delivery efficiency, blood–brain barrier, focused ultrasound, 
permeability
Introduction
Therapeutic agents are often difficult to administer to the brain because the blood–
brain barrier (BBB) has low permeability to ionized water-soluble molecules with 
a molecular mass greater than 180 Da.1 Many approaches have been developed to 
enhance drug delivery to the brain, but these may involve increasing the dosage 
of drugs throughout the brain or may increase the risk of sustaining neurological 
damage. Recent experiments have shown that local and reversible BBB disruption 
(BBB-D) can be accomplished noninvasively using pulsed focused ultrasound (FUS) 
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in the presence of microbubbles; pulsed FUS produces 
mechanical effects such as radiation forces, microstreaming, 
and cavitation that enhance the permeability of the BBB in a 
nondestructive manner. The degree of BBB-D is dependent 
on various ultrasound parameters including acoustic power, 
dosage of ultrasound contrast agent (UCA), and the number 
of sonications that are carried out.2
Many chemotherapy treatments are ineffective because 
drugs fail to reach therapeutic levels in the target brain tumor 
due to limited permeability of the BBB.3 Previous works 
have reported that first-line high-dose chemotherapy provides 
a potential survival benefit compared to historical control 
patients receiving standard-dose therapies.4,5 Traditional 
high-dose chemotherapy can improve treatment efficacy, but 
its clinical application is often limited by systemic toxicity. 
Therefore, it is important to find methods to deliver sufficient 
quantities of drugs to the target region, without increasing 
systemic dosage. We previously reported that the concentration 
of Evans blue (EB) in tumors and the tumor-to-normal brain 
ratio of EB in the brain are elevated after BBB-D induction by 
pulsed FUS. Moreover, repeated pulsed FUS exposure further 
increases the efficiency of EB delivery to the brain.6–9
One study demonstrated that FUS exposure following EB 
injection provides nearly a threefold increase in the amount 
of EB extravasated in sonicated hepatocellular carcinoma 
compared with that from carcinoma sonicated prior to EB 
administration.10 Interestingly, the enhanced efficacy of FUS 
was absent when EB was administered after sonication. 
This result is consistent with a previous report of cardiac 
protein delivery.11 Fluid microjets are responsible for the 
increased capillary permeability and transient nanopores 
observed in cell membranes following FUS destruction 
of microbubbles.12,13 These reports suggest that the drug 
administration procedure must be considered when applying 
FUS treatment with therapeutic agents. Furthermore, FUS 
has been used to enhance local drug delivery and increase the 
antitumor effects in the treatment of brain tumors.14–16
In this study, we evaluated the delivery efficiency of EB 
administration before and after BBB-D induced by FUS. 
In addition, we studied the effects of various ultrasound 
parameters on the efficacy of extravasation. Our aim was 
to optimize FUS mediated drug delivery to the brain, to 
minimize tissue damage.
Materials and methods
Experimental animals
Male Sprague–Dawley rats weighing from 280 to 350 g were 
used in this study. All experiments were performed according 
to the approved protocols of our institutional animal care 
and use committee. Rats were anesthetized with chloral 
hydrate by intraperitoneal injection (400 mg/kg), and body 
temperature was maintained at 37°C using a heating pad. 
The top of the cranium was shaved and the scalp overlying 
the skull was incised to facilitate use of the bregma as an 
anatomic landmark for targeting. The rat heads were mounted 
on stereotaxic apparatus (Stoelting, Wood Dale, IL) with 
the nose bar positioned 3.3 mm below the interaural line. 
Ultrasound transmission gel (Pharmaceutical Innovations, 
Newark, NJ) was used to cover the area between the 
  transducer and the skull to maximize ultrasound transmission. 
In this study, three rats were employed in each group except 
the magnetic resonance imaging (MRI) analysis group which 
used four rats.
Pulsed ultrasound equipment
FUS exposure was provided by a 1 MHz focused transducer 
(A392S; Panametrics, Waltham, MA) with a diameter 
of 38 mm and radius of curvature of 63.5 mm. The half-
maximum of the pressure amplitude at the focal zone was 
3 mm in diameter and 26 mm in length. The acoustic power 
output was measured with a radiation force balance (RFB-
2000; Onda, Sunnyvale, CA). The transducer was mounted 
on a removable cone filled with deionized and degassed 
water, and a polyurethane membrane capped its tip; the center 
of the focal spot was approximately 5.7 mm from the cone tip. 
FUS was precisely targeted using stereotaxic apparatus that 
utilized the bregma as the anatomical target. Pulsed FUS 
was applied with 50 millisecond burst lengths at a 5% duty 
cycle and repetition frequency of 1 Hz. Pulsed FUS was 
delivered to the right hemisphere at a site 3.5 mm posterior 
and 2.5 mm lateral to the bregma, and 5.7 mm below the skull 
surface. UCA (SonoVue; Bracco International, Amsterdam, 
Netherlands), comprising phospholipid-coated microbubbles 
with mean diameter of 2.5 µm at a concentration of 
between 1 × 108 and 5 × 108 bubbles/mL, was intravenously 
administered via the femoral vein approximately 15 seconds 
before sonication.
Experimental protocols
To evaluate the degree of BBB permeability, we compared 
two procedures for EB (100 mg/kg) injection into the rats’ 
femoral vein (Figure 1). The animals received EB injection 
about 5 minutes before or immediately after FUS exposure. 
In the first set of experiments, rats were sonicated with FUS 
in the presence of microbubbles for sonication durations 
of 0 to 60 seconds. In the experiments that followed, we 
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Figure 1 Experimental timeline for pulsed FUS-induced BBB disruption. EB was injected intravenously before (A), or after (B), FUS exposure.
Note: Sonication was applied 15 seconds after microbubble administration to the brain. 
Abbreviations: BBB, blood–brain barrier; EB, Evans blue; FUS, focused ultrasound.
quantified EB accumulation in rat brains after sonication 
for 60 seconds. In the second set of experiments, rats were 
injected with UCA at 300 µL/kg approximately 15 seconds 
prior to FUS exposure at various acoustic powers (0, 1.43, 
2.86, and 4.29 W). In the third set of experiments, rats were 
exposed to a sonication power of 2.86 W in the presence of 
microbubbles at four doses (0, 150, 300, and 450 µL/kg). In 
the final experiment, rats received an injection of gadolinium 
about 5 minutes before or immediately after FUS exposure, 
for MRI analysis.
Quantification of EB accumulation
The permeability of the BBB can be quantified based on 
the extravasation of EB (Sigma, St Louis, MO), which acts 
as a marker of albumin extravasation.9,17,18 EB-treated rats 
were sacrificed approximately 4 hours after sonication. The 
rats were perfused with saline via the left ventricle, until a 
colorless perfusion fluid appeared from the right atrium. After 
perfusion and brain removal, the brain was sectioned into three 
slices from 0 mm to 6 mm posterior to the bregma, and these 
were mounted on glass slides. The coronal sections were then 
divided into right and left hemispheres before measuring 
the amount of EB extravasated. The rats’ nonsonicated left 
hemispheres acted as the control. Samples were weighed 
and then soaked in 50% trichloroacetic acid solution. After 
homogenization and centrifugation, the extracted dye was 
diluted with ethanol (1:3), and the amount of EB present 
determined using a spectrophotometer (PowerWave 340; 
BioTek, Winooski, VT) at 620 nm.19 The EB present in 
the tissue samples was quantified using a linear regression 
standard curve derived from seven concentrations of the 
dye; the amount of dye was expressed in absorbance per 
gram of tissue.
MRI
Contrast enhancement of the T1-weighted MRI was used 
to monitor the BBB-D permeability. Following FUS 
sonication, MRI was performed using a 3T MRI system 
(TRIO 3-T MRI; Siemens AG MAGNETOM, Erlangen, 
Germany). Rats were anesthetized with 1.5% isoflurane 
mixed with oxygen gas, and maintained at 1% isoflurane 
throughout the imaging procedure. A small loop coil (Loop 
Flex Coil; Siemens) approximately 4 cm in diameter was 
used for radio frequency reception. A multislice spin 
echo sequence was performed to obtain 20 slices of the 
T1-weighted MRI covering the whole brain to image the 
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BBB-D (repetition time/echo time = 435/12 milliseconds; 
matrix = 154 × 256; section thickness = 1.5 mm). The 
imaging plane was located across the center of the focal 
zone, perpendicular to the axis of ultrasound beam. The 
MRI contrast agent gadolinium (Omniscan; GE Healthcare, 
Cork, Ireland) was injected intravenously (1 mmol/kg) about 
5 minutes before or immediately after sonication. MRI con-
trast enhancement was analyzed 60 minutes after gadolinium 
administration. Contour maps describing the spatial distribu-
tion of contrast enhancement were quantified for the BBB-D. 
Regions of contrast enhancement greater than 1.5, 3.0, 4.5, 
and 6.0 standard deviations of the averaged spatial normal 
brain regions were color-coded to facilitate identification.
histological examination
Rats were sacrificed approximately 24 hours after sonication 
for histological assessment. Rats were perfused with saline 
and 10% neutral buffered formalin. The brains were removed 
and embedded in paraffin, and then serially sectioned into 
30 µm thick slices. The slices were stained with hematoxylin 
and eosin (H&E; Thermo-Scientific, Waltham, MA) and 
TUNEL staining (DeadEnd Colorimetric TUNEL system, 
G7130; Promega, Madison, WI). The photomicrographs of 
5 µm thickness for the H&E and TUNEL-stained tissues 
were obtained using a Mirax Scan digital microscope slide 
scanner (Mirax 3D Histech; Carl Zeiss, Rochester, NY) 
with a   Plan-Apochromatic 20/0.8 objective lens. The total 
area of each tissue section and the areas showing apoptosis 
were measured using the Image-Pro Plus software   package 
(Media Cybernetics, Silver Spring, MD) in a blinded manner. 
The percentage of the tissue exhibiting apoptosis was 
calculated as follows: (area of the tissue containing apoptotic 
cells/total area of the tissue sections measured) × 100. In total, 
six tissue sections from each brain were analyzed.
Statistical analysis
All values are shown as means ± standard error of mean 
(SEM). Statistical analysis was performed using the unpaired 
Student’s t-test. Statistical significance was defined as 
P value #0.05.
Results
Effect of sonication duration on BBB-D
Figure 2 shows that BBB permeability was dependent on 
the duration of sonication, whether performed before or 
after EB administration. Moreover, it shows a significant 
increase in EB accumulation for the group of rats that 
received EB injection before sonication, at every time point, 
compared to the EB accumulation in rats that received EB 
after sonication. Both groups showed an absorption phase 
from 0 to 40 seconds, and then exhibited a plateau in EB 
concentration between 40 and 60 seconds.
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Figure 2 The amount of EB extravasation in brain tissue was assessed as a function of sonication time after FUS exposure following (solid circle), and followed by (open 
circle), EB injection at UCA dosage 150 µL/kg. 
Note: *Significant difference between the two groups for the same specific sonication duration at a sonication power of 2.86 W (P , 0.05). 
Abbreviations: EB, Evans blue; FUS, focused ultrasound; UCA, ultrasound contrast agent.
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Procedure of EB administration  
for doxorubicin accumulation
Figure 3 shows the mean extravasation of EB per unit mass of 
brain tissue from the sonicated site for four sonication powers, 
for the same dose of UCA. The degree of EB extravasation 
increased with acoustic power. Additionally, the amount of 
EB extravasation was greater in the group injected before 
sonication than it was in the group receiving EB after 
sonication; this difference was particularly evident for the 
lowest sonication power of 1.43 W (P , 0.05). Figure 4 shows 
that the amount of EB extravasated from sonicated brains 
increased with increasing UCA dose from 0 to 450 µL/kg at 
2.86 W sonication power. Moreover, these concentrations were 
greater in the group receiving EB injection before sonication 
than they were in the group that received EB administration 
after sonication, particularly for the highest UCA dose 
of 450 µL/kg (P , 0.01). Importantly, however, the EB 
extravasation was significantly greater in brains with the EB 
injection followed by sonication for UCA at 300 µL/kg than it 
was for brains with EB administration following sonication for 
UCA at 450 µL/kg (P , 0.05). In contrast to EB concentration 
values for the sonicated brains, only insignificant differences 
were found for the values of control brains at the various 
acoustic powers and UCA doses.
MRI analysis
Figure 5A and C shows MRIs depicting the spatial distribution 
of gadolinium deposition in rats receiving administration of 
gadolinium followed by sonication at a power of 2.86 W, for 
UCA doses of 300 and 450 µL/kg. The intensity of the contrast 
enhancement was greater after injecting UCA at 450 µL/kg 
than it was for UCA at 300 µL/kg. Figure 5B shows the dis-
tribution of gadolinium deposition from rats receiving gado-
linium injection following sonication at an acoustic power 
of 2.86 W, for the UCA dose of 450 µL/kg. Interestingly, 
there was less intensity in the contrast enhancement after 
injecting UCA at 450 µL/kg (Figure 5B) than the intensity 
resulting from 300 µL/kg UCA (Figure 5A). The contour 
maps in this figure show the extent of gadolinium deposition; 
there is clearly a better focused gadolinium distribution (red 
and blue regions) in brains receiving sonication following 
gadolinium administration in Figure 5A and C compared to 
brains that received sonication followed by gadolinium injec-
tion (Figure 5B). Following gadolinium administration, the 
normalized signal intensity change in focal volume was sig-
nificantly greater after injecting UCA at 450 µL/kg than it was 
at 300 µL/kg for the same sonication power (Figure 6). The 
normalized signal intensity change in rat brains that received 
a UCA dose of 450 µL/kg and sonicated after gadolinium 
injection was significantly greater than in rats undergoing 
sonication followed by gadolinium administration. It was also 
found that the normalized signal intensity change in the rats 
that received UCA at 300 µL/kg and sonication following 
gadolinium administration was significantly greater than in 
rats that received a UCA dose of 450 µL/kg with sonication 
followed by gadolinium administration.
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Figure 3 Relationship between EB extravasation and sonication power after microbubble and FUS treatment, following and followed by, EB injection at the UCA dose of 
300 µL/kg. EB extravasation as a function of the acoustic power in the presence of microbubbles.
Notes: *Significant difference compared to the contralateral nonsonicated hemisphere; #Significant difference between two sonicated groups. (* and #, P , 0.05). 
Abbreviations: EB, Evans blue; FUS, focused ultrasound; MB, microbubble; UCA, ultrasound contrast agent.
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Figure 4 Relationship between EB extravasation and UCA dosage after FUS treatment, following and followed by, EB injection at a sonication power of 2.86 W. 
Notes: *Significant difference compared with the contralateral nonsonicated hemisphere; #Significant difference between two sonicated groups. (* and #, P , 0.05; ##, P , 0.01). 
Abbreviations: EB, Evans blue; FUS, focused ultrasound; MB, microbubble; UCA, ultrasound contrast agent.
Figure 5 Distribution of BBB disruption for gadolinium administration (A) followed by sonication at 2.86 W with UCA doses of 300 µL/kg and (B) following sonication at 
2.86 W with the UCA dose of 450 µL/kg and (C) 450 µL/kg. 
Notes: The right hemisphere was treated with FUS, and the left was the control. Regions with contrast enhancement are shown as .1.5 (green), .3.0 (yellow), .4.5 (blue), 
and .6.0 (red) standard deviations above the average MRI signal intensity of the contralateral normal tissue in the left hemisphere are shown. 
Abbreviations: BBB, blood–brain barrier; FUS, focused ultrasound; MRI, magnetic resonance imaging; UCA, ultrasound contrast agent.
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Figure 6 Normalized signal intensity change of the contrast-enhanced T1 weighted MRIs in sonicated brains derived from Figure 5. 
Note: **P , 0.01. 
Abbreviations: FUS, focused ultrasound; gd, gadolinium; MRI, magnetic resonance imaging; SI, signal intensity.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2578
Yang and LeeInternational Journal of Nanomedicine 2012:7
histological evaluation
Figure 7 shows representative H&E-stained sections for 
UCA treatments at 300 and 450 µL/kg at sonication power 
of 2.86 W. The corresponding TUNEL-stained sections were 
prepared for histopathologic examination and apoptotic 
evaluation (Figure 8). Red blood cells were present in 
sonicated brain tissue in and around the focal region, and were 
more severe for the higher dose (450 µL/kg) samples. This 
observation is consistent with the finding that more apoptotic 
cells were present in sonicated UCA 450 µL/kg samples than 
they were in UCA 300 µL/kg samples. Figure 9 indicates 
that there were significant differences between these two 
groups.
Discussion
This study demonstrated that drug administration strategy 
has an impact on the efficacy of FUS induced BBB-D, and 
on the resulting efficiency of drug delivery. Interactions 
between sonication and microbubbles can further promote 
extravasation in sonicated regions of the brain. EB 
extravasation in the group of rats injected with EB before 
sonication was significantly greater than in the group injected 
with EB after sonication at every time point (Figure 2). These 
results indicate that a phenomenon other than diffusion, such 
as cavitation, microstreaming, and oscillation, increases 
extravasation when EB is injected prior to sonication. This 
is in agreement with a previous report,10 where significantly 
increased extravasation occurred in hepatomas that were 
sonicated after administration of EB, but not in hepatomas 
sonicated before EB injection.
Our results indicate that the promoted extravasation by 
EB injection before sonication was most significant at the 
lowest acoustic power of 1.43 W and at the highest UCA 
dose of 450 µL/kg. In particular, EB extravasation for EB 
injection before sonication for the UCA 300 µL/kg group 
was significantly greater than for EB injection after soni-
cation for the UCA 450 µL/kg group. The implication of 
this finding is that sonication after drug administration is 
associated with further increases in drug accumulation even 
though UCA is administered at a lower dose. A greater UCA 
  dosage provides more microbubbles in blood vessels to serve 
as nuclei for cavitation, thus augmenting extravasation.18,20 
However, increased numbers of microbubbles can induce 
extravasation of erythrocytes and increase the numbers 
Figure 7 Hematoxylin and eosin staining of transverse brain sections sonicated at 2.86 W with UCA doses of (A–C) 300 µL/kg and (D–F) 450 µL/kg.
Notes: The affected brain structures include the hypothalamus, thalamus, and hippocampus. Local displacement and increased extravasation of red blood cells were more 
obvious in specimens treated at the greater UCA dosage of 450 µL/kg than in specimens treated with UCA doses of 300 µL/kg. 
Abbreviation: UCA, ultrasound contrast agent.
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of apoptotic cells.17 This might explain why the apoptotic 
cells were mainly localized to the microvascular walls, 
with only a few apoptotic cells observed outside the focal 
regions. Therefore, it is essential to optimize ultrasound 
parameters for lower sonication powers and reduced 
UCA doses, to induce BBB-D while minimizing damage 
to normal brain tissue.
The exact mechanism of BBB-D induction by FUS 
remains unclear. Several studies report that the BBB-D 
is probably the result of mechanical effects associated 
Figure 8 Examples of histological observations of TUNEL-stained sections treated with UCA doses of (A–C) 300 µL/kg and (D–F) 450 µL/kg sonicated at 2.86 W. 
Note: Many cells appear to be undergoing apoptosis in the sonicated brains. 
Abbreviation: UCA, ultrasound contrast agent.
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Figure 9 Percentage of apoptotic cells counted in microscopic fields (total area: 4000 × 9000 µm) of the sonicated brains during histological observations of TUNEL-stained 
sections. 
Note: *P , 0.05.
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with interactions between ultrasound and microbubbles. 
Microbubbles have potential therapeutic application in caus-
ing tissue damage and increasing blood vessel permeability 
in muscle.21,22 Furthermore, our previous works found that 
higher doses of UCA, or increased FUS sonication power 
produced longer lasting disruption of the BBB.7,9 Safety 
may become a concern if BBB-D is prolonged, because 
an impermeable BBB is vital to maintaining normal brain 
physiology. Thus, the procedure for drug administration 
is another potentially important factor in enhancing drug 
delivery by FUS under mild sonication conditions to mini-
mize adverse effects. In addition to assessing histology, we 
also monitored patterns of contrast enhancement. The MRIs 
shown in Figure 5 are contour maps revealing that gadolinium 
deposition in rats injected with gadolinium prior to sonication 
is more concentrated in the focal region than the gadolinium 
concentration that occurs when gadolinium injection follows 
sonication. One explanation could be that cavitation activity 
enhances the accumulation of gadolinium in the focal region 
when gadolinium is administered prior to sonication.
In conclusion, this study demonstrates that cavitation 
induced by FUS in the presence of microbubbles   significantly 
increases the delivery efficiency of EB to the brain, if 
  sonication is carried out after EB administration. Our findings 
will aid the development of an optimal procedure for FUS 
assisted drug delivery to the brain while minimizing brain 
tissue damage.
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